> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kite Pharma Begins BLA for CAR-T Cell Therapy
- URL: https://www.fdaweb.com/kite-pharma-begins-bla-for-car-t-cell-therapy/
- Published: 2016-12-05T12:00:00.000Z
- Updated: 2026-09-14T21:52:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5137490

Kite Pharma has begun a rolling BLA submission for KTE-C19 (axicabtagene ciloleucel) as a treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for autologous stem cell transplant. The submission is supported by data from the company’s pivotal ZUMA-1 study that enrolled patients with chemorefractory diffuse large B-cell lymphoma, transformed follicular lymphoma, and primary mediastinal B-cell lymphoma — three subtypes of aggressive NHL. The company expects to complete its BLA submission by the end of the first quarter of 2017\. Axicabtagene ciloleucel is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells, according to the company.